HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Free All Versions of this Article: 98/1/180    most recent 00913.2004v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Burki, N. K. Articles by Lee, L.-Y. Search for Related Content PubMed PubMed Citation Articles by Burki, N. K. Articles by Lee, L.-Y.

Intravenous adenosine and dyspnea in humans

¹Division of Pulmonary Medicine, Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut; ²Department of Medicine, University of Kentucky Medical Center, and ³Department of Physiology, University of Kentucky, Lexington, Kentucky

Submitted 20 August 2004 ; accepted in final form 15 September 2004

	ABSTRACT

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
Intravenous adenosine for the treatment of supraventricular tachycardia is reported to cause bronchospasm and dyspnea and to increase ventilation in humans, but these effects have not been systematically studied. We therefore compared the effects of 10 mg of intravenous adenosine with placebo in 21 normal subjects under normoxic conditions and evaluated the temporal sequence of the effects of adenosine on ventilation, dyspnea, and heart rate. The study was repeated in 11 of these subjects during hyperoxia. In all subjects, adenosine resulted in the development of dyspnea, assessed by handgrip dynamometry, without any significant change (P > 0.1) in lung resistance as measured by the interrupter technique. There were significant increases (P < 0.05) in ventilation and heart rate in response to adenosine. The dyspneic response occurred slightly before the ventilatory or heart rate responses in every subject, but the timing of the dyspneic, ventilatory, and heart rate responses was not significantly different when the group data were analyzed (18.9 ± 5.8, 20.3 ± 5.5, and 19.7 ± 4.5 s, respectively). During hyperoxia, adenosine resulted in similar effects, with no significant differences in the magnitude of the ventilatory response; however, compared with the normoxic state, the intensity of the dyspneic response was significantly (P < 0.05) reduced, whereas the heart rate response increased significantly (P < 0.05). These data indicate that intravenous adenosine-induced dyspnea is not associated with bronchospasm in normal subjects. The time latency of the response indicates that the dyspnea is probably not a consequence of peripheral chemoreceptor or brain stem respiratory center stimulation, suggesting that it is most likely secondary to stimulation of receptors in the lungs, most likely vagal C fibers.

asthma; pulmonary vagal C fibers; ventilation; chemoreceptors

We therefore studied normal human subjects to measure the temporal relationship of dyspnea and changes in ventilation after bolus intravenous adenosine administration to ascertain whether these effects are related to chemoreceptor activation or a consequence of direct pulmonary vagal receptor activation. We also examined the effects of hyperoxia on the response to adenosine to further differentiate the contribution of carotid chemoreceptors and pulmonary vagal receptors.

	METHODS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
Twenty-one healthy, nonsmoking subjects (mean age 26.6 ± 8.0 yr, range 18–48 yr, 8 women) were studied; written, informed consent was obtained from each subject.

The subject was seated, and a forearm vein was cannulated and connected to a normal saline drip. A curtain between the subject and the cannulated forearm prevented the subject from being able to see when an injection was given (see below). Minute ventilation (E) and ventilatory pattern were recorded with the subject breathing via a mouthpiece attached to a two-way valve (Hans-Rudolph, Kansas City, MO); expiratory flow was recorded on a multichannel recorder (Grass Medical Instruments, Astro-Med, West Warwick, RI) as the differential pressure signal from a heated pneumotachygraph on the expiratory side of the valve, which was connected to a differential pressure transducer (Hans-Rudolph). The flow signal was electronically integrated to volume and recorded. The system was calibrated before each experiment, using a calibrated syringe (Spirometrix).

Airways resistance (Rint) was measured by the interrupter technique (6, 24, 28) at baseline and 90 s after the adenosine injection. Inspiratory flow was interrupted with an electronically operated shutter at a flow rate of 0.5 l/s, and the change in mouth pressure, measured at the mouthpiece by a pressure transducer, was related to the flow rate to calculate Rint.

Each subject indicated the presence and intensity of dyspneic sensation by squeezing an isometric handgrip dynamometer (6, 32, 55); the resultant voltage deflection was recorded and measured as millimeters of deflection from baseline. The subject was instructed to respond immediately when any sensation was felt with a magnitude of handgrip force proportional to the intensity of the sensation. Subjects were asked to focus on respiratory symptoms such as chest tightness, shortness of breath, increased urge to breathe, burning sensation in the chest and throat; preliminary studies by N. K. Burki, M. Alan, and L.-Y. Lee had indicated that the commonest symptoms expressed were shortness of breath and chest tightness.

End-tidal CO₂ was sampled at the mouthpiece and analyzed by a CO₂ meter (Ohmeda, Englewood, CO), the output from which was continuously recorded.

Arterial O₂ saturation (Sa_O2) was recorded continuously by using a pulse oximeter (Criticare Systems, Waukesha, WI). Electrocardiogram lead II was recorded continuously, and heart rate (HR) was measured from the R-R interval.

Baseline measurements of Rint were made, and when the subject had a stable breathing pattern (as judged by <5% variation in the end-tidal CO₂), E, ventilatory pattern, end-tidal CO₂, HR, and Sa_O2 were recorded over 3 min, and a baseline handgrip dynamometry score was recorded.

The subject then received an injection of 10 mg of adenosine, with care being taken to avoid awareness of the injection by the subject. The time latency between the bolus injection and the initial change in E (measured as the onset of the first breath exhibiting an increase in volume or frequency), handgrip (measured as the beginning of the first deflection from baseline of the dynamometer tracing), and HR (measured as the beginning of the first R-R interval change) were measured. Further measurements of E (calculated from 2–3 breaths within a 10-s time bloc at each measurement time), handgrip dynamometry, end-tidal CO₂, Sa_O2, and HR were made continuously over the next 3 min; preliminary studies by N. K. Burki, M. Alan, and L.-Y. Lee had shown that all measured parameters returned to baseline 90–120 s after adenosine injection. Rint was measured 60–90 s after the injection. In 10 subjects, an injection of 10 ml of normal saline was given before the injection of adenosine, and the response was recorded in the same manner. In 11 subjects, the study was performed under both normoxic and hyperoxic conditions; the sequence of the studies, normoxia and hyperoxia, was varied randomly such that in 5 subjects the normoxic study was performed before the hyperoxic study and the order was reversed in the other 6. Under hyperoxic conditions, the subject breathed 100% O₂ from a Douglas bag attached to the inspiratory side of the two-way valve for 10 min before the adenosine injection.

Differences among the initial response times for handgrip, change in E, and change in HR within each condition, normoxia or hyperoxia, were compared by the Student-Newman-Keuls multiple-comparison technique (1). The significance of changes from baseline in handgrip response, E and ventilatory parameters, and HR were analyzed by one-way repeated-measures ANOVA, with post hoc Tukey's analysis (1). Comparison of the effects of adenosine during normoxia compared with hyperoxia were analyzed by two-way ANOVA.

	RESULTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
In the 10 subjects who received placebo injection, there was no significant (P > 0.5) effect on the E, handgrip, ventilatory pattern, Rint, HR, end-tidal CO₂, or Sa_O2.

Rint did not change significantly after adenosine injection (baseline Rint: 2.22 ± 0.37 and 2.24 ± 0.43 cmH₂O·l^–1·s after adenosine; P > 0.1; n = 21). Adenosine injection resulted in significant increases in dyspnea, as represented by handgrip dynamometry, and in E and HR (Table 1). The increase in E was primarily due to an increase in tidal volume, with no significant change in respiratory frequency (Table 1).

The change in handgrip and the percent change from baseline in E and HR are shown in Fig. 1. There were significant increases (P < 0.05) in handgrip and E at 20, 40, and 60 s, whereas, after an initial, nonsignificant slowing of the HR, significant (P < 0.05) tachycardia occurred only at 40 s.

View larger version (17K): [in this window] [in a new window]   Fig. 1. Changes in handgrip dynamometry and percent change in minute ventilation (E) and heart rate (HR) after adenosine injection in normal subjects (n = 21). BL, baseline. *Significantly different from baseline, P < 0.05. There were significant increases in handgrip and E at 20 s, continuing to 60 s, but significant tachycardia only occurred at 40 s, after an initial slowing.

The effects of hyperoxia on ventilatory, handgrip dynamometry, and HR responses were similar to those in normoxia (Table 2); however, the magnitudes of the handgrip and HR responses were significantly different (Fig. 2); handgrip was significantly less (P < 0.05) and the percent change from baseline of HR was significantly more (P < 0.05) than in the normoxic state. In contrast, percent change from baseline of E did not differ significantly (P > 0.05).

View larger version (17K): [in this window] [in a new window]   Fig. 2. Comparison of changes in handgrip dynamometry and percent change in E and HR after adenosine injection in normal subjects (n = 11) during normoxia (solid lines) and hyperoxia (dashed lines). Bottom: , %E; , %HR. *Significantly different from normoxia, P < 0.05. The handgrip response was significantly less and the HR response significantly increased during hyperoxia, whereas the ventilatory response did not change significantly between normoxia and hyperoxia.

	DISCUSSION

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

Adenosine is believed to have a direct effect on the sinoatrial and atrial-ventricular nodes, resulting in bradycardia (42). However, intravenous adenosine in normal subjects is known to cause tachycardia (3, 26, 42), and this is believed to be due to increased cardiac sympathetic drive and decreased vagal tone, which overrides the bradycardia caused by its direct effects on the sinoatrial node and atrioventricular conduction (42). In the present study, we noted an initial bradycardia in every subject, as measured by the R-R interval; this was present in each subject for only two to three beats followed by a significant tachycardia. Previous studies in normal subjects have reported no bradycardia (25, 40); however, in these studies, adenosine was not given as a bolus dose but as a continuous infusion, and it is not clear whether HR was averaged from a larger number of beats. In contrast, Biaggioni et al. (3) did note bradycardia in five of nine subjects. On the basis of the time latency of the effect, our data would suggest that the initial bradycardia may be secondary to vagal afferent stimulation (see below), which is then overridden by increasing cardiac sympathetic tone. The novel finding in this study of an increased heart rate response to adenosine during hyperoxia could be explained by an increased sympathetic effect of adenosine or decreased parasympathetic tone; however, this remains to be elucidated.

Among the reported side effects (40) of intravenous adenosine are bronchospasm and dyspnea; however, these are anecdotal reports (3, 40) in asthmatic subjects receiving intravenous adenosine for the treatment of arrhythmia; actual bronchoconstriction has not been documented in these reports by any measurements of airway function. In a study (2) of 122 consecutive patients, including 36 with chronic bronchitis, undergoing adenosine stress testing for myocardial perfusion imaging, dyspnea was noted in over 50% of subjects, but no changes in spirometric indexes were noted; the response latency and the relationship of the dyspnea to ventilation were not further characterized. Changes in spirometric indexes after intravenous adenosine were also absent in other studies (3, 17, 20). However, it could be argued that acute changes in airways resistance may not be detected by spirometry, because the necessity of a deep inspiration before the measurement may itself attenuate any existing bronchoconstriction (8). We measured airways resistance by the interrupter technique in the present study; this measurement is rapid and does not require a deep breath or any special ventilatory maneuver by the subject (6, 24, 28), thus obviating any effects such maneuvers may have in masking an increase in airways resistance (8). Our results confirm that significant changes in airways resistance do not occur after intravenous adenosine. Extensive previous data indicate that the perception of changes in airways resistance and the development of dyspnea in normal and asthmatic subjects occurs with significant and relatively large changes in airways resistance (7, 19, 33, 34, 38, 43, 48). Thus any changes in airway smooth muscle tone and airways resistance not reflected in Rint are unlikely to be of significance relative to the observed dyspnea. Our data confirm that the sensation of dyspnea or chest tightness reported in normal subjects is not related to bronchospasm.

On the other hand, inhaled adenosine and adenosine 5'-monophosphate are known to cause bronchoconstriction in asthmatic human subjects (12, 14), probably via mast cell mediator release. However, this effect has only been demonstrated with inhaled adenosine, and has not been demonstrated with parenteral adenosine (2, 3, 17, 20), and suggests that the bronchospastic effects of adenosine are related to the route of administration.

The ventilatory effects of adenosine could be due to peripheral chemoreceptor or pulmonary receptor activation. Adenosine activates carotid chemoreceptors in cats (31), and this effect is dose dependent and not related to changes in systemic blood pressure or blood flow (44). In carotid body-denervated cats, adenosine acts as a central respiratory depressant (15). In humans, the ventilatory effects of adenosine have also been ascribed to carotid body chemoreceptor stimulation, but the results have been inconclusive (16, 17, 21, 50). Griffiths et al. (21) studied the ventilatory response to hypoxia and adenosine in five human subjects with carotid endarterectomies with variable results; Engelstein et al. (16) noted increased sympathetic activity and ventilation with dipyridamole, which increases endogenous adenosine concentration and activity but did not specifically exclude causes other than chemoreceptor stimulation for the increase in ventilation. Fuller et al. (17) provided persuasive evidence of carotid chemoreceptor activation by adenosine on the basis of the site of infusion in the aorta; nevertheless, the evidence was not conclusive. Similarly, whereas some studies have shown that intravenous adenosine enhances the hypoxic ventilatory response (30, 53), other studies (37) have not supported this conclusion.

Dyspnea, or shortness of breath (4, 5, 29), is a common accompaniment of most lung diseases. However, knowledge of this sensation remains imperfect, and a number of theories have been put forth as to the genesis of this sensation (4, 5). It is now generally accepted that the sensation(s) of dyspnea involves central, chemoreceptor, and peripheral (chest wall mechanoreceptor and lung receptor) mechanisms (5, 29, 49). The adenosine-induced dyspnea documented in the present study could be due to a direct central effect, chemoreceptor stimulation, or stimulation of pulmonary receptors. Previous animal and human studies of chemoreceptor response time after peripheral intravenous injection (11, 13, 18, 51) make it very unlikely that the dyspnogenic or ventilatory responses noted in the present study can be secondary to a direct central dyspnogenic effect.

Two considerations argue against carotid chemoreceptor activation as an explanation of the ventilatory and dyspnogenic effects: the time latency of the effects and the effects of hyperoxia. Studies (18, 51) indicate that the circulation time in humans between a peripheral intravenous injection and the pulmonary circulation ranges between 15 and 20 s. In contrast, between the central veins and the radial artery, the minimum circulation time ranges between 19 and 24 s (41). This makes it unlikely that the bolus injection of adenosine into a peripheral vein resulting in dyspnea and ventilatory effects in 19–20 s could be attributed to carotid chemoreceptor activation. In addition, during hyperoxia, there was no change in the increase in ventilation after adenosine, whereas dyspnea was significantly attenuated; this argues further against a role for the carotid chemoreceptors. Indeed, the time latency argues toward a pulmonary receptor effect. Maxwell et al. (30) first suggested that the ventilatory effects of adenosine may be mediated by intrapulmonary receptors.

Sensory receptors in the lungs consist of stretch and irritant receptors in the large airways, innervated both by myelinated fibers of the vagus nerve and by unmyelinated vagal C fibers (11). The irritant receptors appear to modify the intensity of dyspnea associated with induced bronchoconstriction (48), and airway stretch receptors appear to modify breathlessness by altering ventilatory pattern (22, 52). However, neither of these receptors has been shown to be specifically dyspnogenic.

Vagal afferent C fibers lie in close proximity to the pulmonary capillaries and alveoli, and they are also present in the mucosa and deeper tissue of the conducting airways (11). Coleridge and coworkers (11) from studies in larger mammals (i.e., dogs and cats) have subdivided them further into pulmonary and bronchial groups, on the basis of pulmonary and bronchial arterial blood supply, and have suggested that the groups have different sensitivities to chemical and mechanical stimuli. However, this concept of different physiological and pharmacological properties between "airway" and "pulmonary" C fibers has been challenged by other investigators (45) on the grounds that substantial vascular anastomosis exists between the bronchial and pulmonary circulations (9). Pulmonary C fibers are now considered synonymous (18, 36) with the "J" receptors described by Paintal (35) in the lung parenchyma.

In humans, pulmonary C fibers have been implicated in the sensation of dyspnea (36), although direct evidence of this has been hard to obtain (46). Human studies attempting to characterize C fibers have utilized intravenous lobeline or intravenous or aerosolized capsaicin; these produce coughing and burning or irritating sensations in the throat and midsternum (18, 25, 36, 39, 51). These sensations are often so powerful that they limit the dose of the drug that can be administered. However, the development of a cough raises the possibility that other receptors, such as the irritant receptors, may also be stimulated by these drugs (18).

Evidence implicating a role for airway and/or alveolar C fibers in dyspnea comes from studies of nebulized morphine in dypneic patients (54), which reduced exercise-induced dyspnea, and the finding of an increase in exercise-induced dyspnea in normal subjects after inhalation of prostaglandin E₂, which is known to increase vagal afferent C-fiber sensitivity (47). Thus, whereas previous evidence is suggestive, the results of studies of dyspnea and the role of pulmonary vagal C fibers have been inconclusive.

A study in rats in our laboratory (23) provided the first evidence that adenosine stimulates pulmonary C fibers through activation of A₁ receptors. In the present study, our experiments were designed to specifically measure the time latency of response, and the results indicate that dyspnea develops before the ventilatory response, making it unlikely that the dyspnea was secondary to the increase in ventilation. Similarly, because the dyspnea occurred before any change in HR, it is unlikely that it was a response to the tachycardia. Although we have no direct evidence, our animal data (23, 27) would suggest that the dyspnea is caused by direct stimulation of pulmonary C-fiber endings by adenosine. In rats, the respiratory reflex response to adenosine is completely blocked by selective blockade of conduction of the pulmonary C fibers (27). The probability that the dyspnea is caused by stimulation of C fibers is further supported by the fact that C-fiber stimulation with adenosine in nonhuman primates stimulates ventilation and results in an initial bradycardia as seen in the present study (13).

It has been suggested (10) that hyperoxia may directly influence the cerebral cortex to modify the perception of sensory information, and this may explain the attenuation of the dyspnogenic effects of adenosine during hyperoxia. This attenuation of the dyspnogenic effect of intravenous adenosine by hyperoxia, in the absence of any significant change in the ventilatory response, would suggest that there is a complex interrelationship between the peripheral effects of adenosine and the central perception of dyspnea.

In conclusion, this study has shown that intravenous adenosine results in dyspnea in normal subjects and that it also causes an increase in ventilation; however, the dyspnogenic effect is clearly not a consequence of the increase in ventilation. The timing of the dyspnogenic response makes it unlikely that it is secondary to carotid chemoreceptor activation, and it is possible that it is a consequence of direct stimulation of pulmonary vagal C fibers.

	GRANTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
This work was supported by National Heart, Lung, and Blood Institute Grant RO1 HL-65486.

	ACKNOWLEDGMENTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
We are grateful to Christopher Semder for assistance with the study.

	FOOTNOTES

 

Address for reprint requests and other correspondence: N. K. Burki, Div. of Pulmonary Medicine, Dept. of Medicine, Univ. of Connecticut Health Center, 263 Farmington Ave., Farmington, CT 06030-1225 (E-mail: nburki{at}uchc.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

	REFERENCES

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 

1. Armitage P, Berry G, and Matthews JNS. Statistical Methods in Medical Research (4th ed.). Ames, IA: Iowa State University Press, Blackwell Science, 2002, p. 225–227 and 432–435.
2. Balan KK and Critchley M. Is the dyspnea during adenosine cardiac stress test caused by bronchospasm? Am Heart J 142: 142–145, 2001.[CrossRef][ISI][Medline]
3. Biaggioni I, Olafsson B, Robertson RM, Hollister AS, and Robertson D. Cardiovascular and respiratory effects of adenosine in conscious man. Evidence for chemoreceptor activation. Circ Res 61: 779–786, 1987.[Abstract/Free Full Text]
4. Burki NK. Breathlessness and mouth occlusion pressure in patients with chronic obstruction of the airways. Chest 76: 527–531, 1979.[Medline]
5. Burki NK. Dyspnea. Clin Chest Med 1: 47–55, 1980.[ISI][Medline]
6. Burki NK. Effects of bronchodilation on magnitude estimation of added resistive loads in asthmatic subjects. Am Rev Respir Dis 129: 225–229, 1984.[ISI][Medline]
7. Burki NK, Mitchell K, Chaudhary BA, and Zechman FW. The ability of asthmatics to detect added resistive loads. Am Rev Respir Dis 117: 71–75, 1978.[ISI][Medline]
8. Burns CB, Taylor WR, and Ingram RH Jr. Effects of deep inhalation in asthma: relative airway and parenchymal hysteresis. J Appl Physiol 59: 1590–1596, 1985.[Abstract/Free Full Text]
9. Charan NB, Albert RK, Lakshminarayan S, Kirk W, and Butler J. Factors affecting bronchial blood flow through bronchopulmonary anastomoses in dogs. Am Rev Respir Dis 134: 85–95, 1986.[ISI][Medline]
10. Chronos N, Adams L, and Guz A. Effect of hyperoxia on exercise-induced breathlessness in normal subjects. Clin Sci (Lond) 74: 531–537, 1988.[Medline]
11. Coleridge JCG and Coleridge HM. Afferent vagal C fibre innervation of the lungs and airways and its functional significance. Rev Physiol Biochem Pharmacol 99: 1–110, 1984.[CrossRef][ISI][Medline]
12. Cushley MJ, Tattersfield AE, and Holgate ST. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 15: 161–165, 1983.[ISI][Medline]
13. Deep V, Singh M, and Ravi K. Role of vagal afferents in the reflex effects of capsaicin and lobeline in monkeys. Respir Physiol 125: 155–168, 2001.[CrossRef][ISI][Medline]
14. Egbagbe E, Pavord ID, Wilding P, Thompson-Coon J, and Tattersfield AE. Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline. Thorax 52: 239–243, 1997.[Abstract]
15. Eldridge FL, Millhorn DE, and Kiley JP. Antagonism by theophylline of respiratory inhibition induced by adenosine. J Appl Physiol 59: 1428–1432, 1985.[Abstract/Free Full Text]
16. Engelstein ED, Lerman BB, Somers VK, and Rea RF. Role of arterial chemoreceptors in mediating the effects of endogenous adenosine on sympathetic nerve activity. Circulation 90: 2919–2926, 1994.[Abstract/Free Full Text]
17. Fuller RW, Maxwell DL, Conradson TBG, Dixon CMS, and Barnes PJ. Circulatory and respiratory effects of infused adenosine in conscious man. Br J Clin Pharmacol 24: 309–317, 1987.
18. Gandevia SC, Butler JE, Taylor JL, and Crawford MR. Absence of viscerosomatic inhibition with injections of lobeline designed to activate human pulmonary C fibers. J Physiol 511: 289–330, 1998.[Abstract/Free Full Text]
19. Gotfried SB, Altose MD, Kelsen SG, and Cherniack NS. Perception of changes in airflow resistance in obstructive pulmonary disorders. Am Rev Respir Dis 124: 566–570, 1981.[ISI][Medline]
20. Griffiths TL, Fernando SSD, and Saunders KB. Effect of adenosine infusion on oxygen induced carbon dioxide retention in severe chronic obstructive pulmonary disease. Thorax 51: 1083–1086, 1996.[Abstract]
21. Griffiths TL, Warren SJ, Chant AD, and Holgate ST. Ventilatory effects of hypoxia and adenosine infusion in patients after bilateral carotid endarterectomy. Clin Sci (Lond) 78: 25–30, 1990.[Medline]
22. Guz A, Noble MIM, and Eisele JH. Experimental results of vagal block in cardiopulmonary disease. In: Breathing: Hering-Breuer Centenary Symposium, edited by Porter R. London: Churchill and Livingstone, 1970, p. 315–329.
23. Hong JL, Ho CY, Kwong K, and Lee LY. Activation of pulmonary C fibers by adenosine in anaesthetized rats: role of adenosine A1 receptors. J Physiol 508: 109–118, 1998.[Abstract/Free Full Text]
24. Jackson AC, Milhorn HT, and Norman JR. A reevaluation of the interrupter technique for airway resistance measurements. J Appl Physiol 36: 264–268, 1974.[Free Full Text]
25. Jain SK, Subramanian S, Julka DB, and Guz A. Search for evidence of lung chemoreflexes in man: study of respiratory, and circulatory effects of phenyldiguanide and lobeline. Clin Sci (Lond) 42: 163–177, 1972.
26. Johnston DL, Hodge DO, Hopfenspirger MR, and Gibbons RJ. Clinical determinants of hemodynamic and symptomatic responses in 2,000 patients during adenosine scintigraphy. Mayo Clin Proc 73: 314–320, 1998.[ISI][Medline]
27. Kwong K, Hong JL, Morton RF, and Lee LY. Role of pulmonary C fibers in adenosine-induced respiratory inhibition in anesthetized rats. J Appl Physiol 84: 417–424, 1998.[Abstract/Free Full Text]
28. Liistro G, Stanescu D, Rodenstein D, and Veriter C. Reassessment of the interruption technique for measuring airflow resistance in humans. J Appl Physiol 67: 933–937, 1989.[Abstract/Free Full Text]
29. Manning HL and Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med 333: 1547–1553, 1995.[Free Full Text]
30. Maxwell DL, Fuller RW, Nolop KB, Dixon CMS, and Hughes JMB. Effects of adenosine on ventilatory responses to hypoxia and hypercapnia in man. J Appl Physiol 61: 1762–1766, 1986.[Abstract/Free Full Text]
31. McQueen DS and Ribiero JA. On the specificity and type of receptor involved in carotid body chemoreceptor activation by adenosine in the cat. Br J Pharmacol 80: 347–354, 1983.[ISI][Medline]
32. Muza SR and Zechman FW. Scaling of added loads to breathing: magnitude estimation vs. handgrip matching. J Appl Physiol 57: 888–891, 1984.[Abstract/Free Full Text]
33. Orehek J, Beaupre A, Badier M, Nicoli MM, and Delpierre S. Perception of airway tone by asthmatic patients. Bull Eur Physiopath Respir 18: 601–607, 1982.[ISI][Medline]
34. Ottanelli R, Rosi E, Romagnoli I, Ronchi MC, Lanini B, Grazzini M, Filippelli M, Stendardi L, Duranti R, and Scano G. Perception of bronchoconstriction and bronchial hyperresponsiveness in asthma. Clin Sci (Lond) 98: 681–687, 2000.[Medline]
35. Paintal AC. Mechanisms of stimulation of type J pulmonary receptors. J Physiol 203: 511–532, 1969.[Abstract/Free Full Text]
36. Paintal AC. Sensations from J receptors. News Physiol Sci 10: 238–243, 1995.[Abstract/Free Full Text]
37. Parsons ST, Griffiths TL, Christie JML, and Holgate ST. Effects of theophylline and dipyridamole on the respiratory response to isocapnic hypoxia in normal human subjects. Clin Sci (Lond) 80: 107–112, 1991.[Medline]
38. Peiffer C, Toumi M, Razzouk H, Marsac J, and Lockhart A. Relationship between spontaneous dyspnoea and lability of airway obstruction in asthma. Clin Sci (Lond) 82: 717–724, 1992.[Medline]
39. Raj H, Singh VK, Anand A, and Paintal AS. Sensory origin of lobeline-induced sensations: a correlative study in man and cats. J Physiol 482: 235–246, 1995.[Abstract/Free Full Text]
40. Rankin AC, Brooks R, Ruskin JN, and McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med 92: 655–664, 1992.[CrossRef][ISI][Medline]
41. Roerig DL, Kotrly KJ, Vucins EJ, Ahif SB, Dawson CA, and Kampine JP. First pass uptake of fentanyl, meperidine, and morphine in the human lung. Anesthesiology 67: 466–472, 1987.[CrossRef][ISI][Medline]
42. Rongen GA, Brook SC, Pollard MJ, Ando SI, Dajani HR, Notarius CF, and Floras JS. Effect of adenosine on heart rate variability in humans. Clin Sci (Lond) 96: 597–604, 1999.[Medline]
43. Rubinfeld AR and Pain MCF. Conscious perception of bronchospasm as a protective phenomenon in asthma. Chest 72: 154–158, 1977.[Medline]
44. Runold M, Cherniack NS, and Prabhakar NR. Effect of adenosine on isolated and superperfused cat carotid body activity. Neurosci Lett 113: 111–114, 1990.[CrossRef][ISI][Medline]
45. Sant'Ambrogio FB and Sant'Ambrogio G. Circulatory accessibility of nervous receptors localized in the tracheobronchial tree. Respir Physiol 49: 49–73, 1982.[CrossRef][ISI][Medline]
46. Stark RD, O'Neill PA, Russell NJW, Russell NJ, Heapy CG, and Stretton TB. Effects of small-particle aerosols of local anaesthetic on dyspnoea in patients with respiratory disease. Clin Sci (Lond) 69: 29–36, 1985.[Medline]
47. Taguchi O, Kikuchi Y, Hida W, Iwase N, Okabe S, Chonan T, and Takishima T. Prostaglandin E₂ inhalation increases the sensation of dyspnea during exercise. Am Rev Respir Dis 145: 1346–1349, 1992.[ISI][Medline]
48. Taguchi O, Kikuchi Y, Hida W, Iwase N, Sato M, Chonan T,and Takishima T. Effects of bronchoconstriction and external resistive loading on the sensation of dyspnea. J Appl Physiol 71: 2183–2190, 1991.[Abstract/Free Full Text]
49. Tobin MJ. Dyspnea. Pathological basis, clinical presentation, and management. Arch Intern Med 150: 1604–1613, 1990.[CrossRef][ISI][Medline]
50. Watt AH, Reid PG, Stephens MR, and Routledge PA. Adenosine-induced respiratory stimulation in man depends on site of infusion. Evidence for an action on the carotid body? Br J Clin Pharmacol 23: 486–490, 1987.[ISI][Medline]
51. Winning AJ, Hamilton RD, Shea SA, and Guz A. Respiratory and cardiovascular effects of central and peripheral intravenous injections of capsaicin in man: evidence for pulmonary chemosensitivity. Clin Sci (Lond) 71: 519–526, 1986.[Medline]
52. Winning AJ, Hamilton RD, Shea SA, and Guz A. The effect of airway anaesthesia on the control of breathing and the sensation of breathlessness in man. Clin Sci (Lond) 68: 215–225, 1988.
53. Yamamoto M, Nishimura M, Kobayashi S, Akiyama Y, Miyamoto K, and Kawakami Y. Role of endogenous adenosine in hypoxic ventilatory response in humans: a study with dipyridamole. J Appl Physiol 76: 196–200, 1994.[Abstract/Free Full Text]
54. Young IH, Daviskas E, and Keena VA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax 44: 387–390, 1989.[Abstract]
55. Zechman FW, Wiley RL, and Davenport PW. Ability of healthy men to discriminate between added inspiratory resisitive and elastic loads. Respir Physiol 45: 111–120, 1981.[CrossRef][ISI][Medline]

This article has been cited by other articles:

				C. R. DeSesa, R. P. Vaughan, M. J. Lanosa, K. G. Fontaine, and J. B. Morris Sulfur-Containing Malodorant Vapors Enhance Responsiveness to the Sensory Irritant Capsaicin Toxicol. Sci., July 1, 2008; 104(1): 198 - 209. [Abstract] [Full Text] [PDF]

				R. P. Vaughan, M. T. Szewczyk Jr, M. J. Lanosa, C. R. DeSesa, G. Gianutsos, and J. B. Morris Adenosine Sensory Transduction Pathways Contribute to Activation of the Sensory Irritation Response to Inspired Irritant Vapors Toxicol. Sci., October 1, 2006; 93(2): 411 - 421. [Abstract] [Full Text] [PDF]

				B. Chuaychoo, M.-G. Lee, M. Kollarik, R. Pullmann Jr, and B. J. Undem Evidence for both adenosine A1 and A2A receptors activating single vagal sensory C-fibres in guinea pig lungs J. Physiol., September 1, 2006; 575(2): 481 - 490. [Abstract] [Full Text] [PDF]

				B. J. Undem and M. Kollarik The Role of Vagal Afferent Nerves in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 355 - 360. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Free All Versions of this Article: 98/1/180    most recent 00913.2004v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Burki, N. K. Articles by Lee, L.-Y. Search for Related Content PubMed PubMed Citation Articles by Burki, N. K. Articles by Lee, L.-Y.